TD Asset Management
VRDN icon

TD Asset Management’s Viridian Therapeutics VRDN Stock Holding History

TD Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.33M Buy
235,606
+180,220
+325% +$2.9M ﹤0.01% 833
2026
Q1 		$1.08M Sell
55,386
-58,616
-51% -$1.74M ﹤0.01% 1083
2025
Q4 		$3.55M Buy
114,002
+35,202
+45% +$965K ﹤0.01% 860
2025
Q3 		$1.7M Sell
78,800
-10,800
-12% -$195K ﹤0.01% 1005
2025
Q2 		$1.25M Buy
89,600
+57,000
+175% +$774K ﹤0.01% 1032
2025
Q1 		$439K Sell
32,600
-18,600
-36% -$317K ﹤0.01% 1157
2024
Q4 		$982K Buy
+51,200
New +$1.11M ﹤0.01% 1115

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

TD Asset Management's VRDN Position: Q2 2026 in Review

TD Asset Management increased its Viridian Therapeutics (VRDN) stake by 325% in Q2 2026, buying an estimated $2.9M and bringing the position to 235,606 shares worth $4.33M. The position accounts for ﹤0.01% of the portfolio, ranked #833.

TD Asset Management first reported a position in VRDN in Q4 2024 and has held it in 7 quarters since. 134 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • TD Asset Management held 235,606 shares of Viridian Therapeutics worth $4.33M as of Q2 2026.
  • TD Asset Management bought 180,220 Viridian Therapeutics shares in Q2 2026, an estimated $2.9M.
  • Viridian Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #833 holding.
  • TD Asset Management first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 134 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.